Pear Therapeutics (Pear Therapeutics) Equity-to-Asset : 0.32 (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Pear Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Pear Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $30.59 Mil. Pear Therapeutics's Total Assets for the quarter that ended in Dec. 2022 was $95.13 Mil. Therefore, Pear Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2022 was 0.32.

The historical rank and industry rank for Pear Therapeutics's Equity-to-Asset or its related term are showing as below:

PEARQ's Equity-to-Asset is not ranked ^*
in the Healthcare Providers & Services industry.
Industry Median: 0.47
* Ranked among companies with meaningful Equity-to-Asset only.

Pear Therapeutics Equity-to-Asset Historical Data

The historical data trend for Pear Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pear Therapeutics Equity-to-Asset Chart

Pear Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Equity-to-Asset

-0.60

0.66

0.46

0.32

Pear Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Equity-to-Asset	Get a 7-Day Free Trial							0.46	0.40	0.56	0.44	0.32

Competitive Comparison of Pear Therapeutics's Equity-to-Asset

For the Health Information Services subindustry, Pear Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pear Therapeutics's Equity-to-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pear Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Pear Therapeutics's Equity-to-Asset falls into.

Pear Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Pear Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	30.585	/	95.129
	=	0.32

Pear Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

Equity to Asset (Q: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	30.585	/	95.129
	=	0.32

Pear Therapeutics (OTCPK:PEARQ) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Pear Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Pear Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pear Therapeutics (Pear Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pear Therapeutics Inc (OTCPK:PEARQ) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 State Street, 13th Floor, Boston, MA, USA, 02109

Website

https://www.peartherapeutics.com

Pear Therapeutics Inc is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDTs), which use software to treat diseases directly. The company's vision is to advance healthcare through the widespread use of PDTs and to be the one-stop shop for PDTs offered by Pear and other organizations that may choose to make their products available to patients, providers, and payors via its commercial platform, known as PearConnect. It features four distinct system components, consisting of PDTs for patient use, the PearMD Clinician Dashboard, an end-to-end patient service center, and a data analytics system configured to aggregate patient engagement, adherence, and clinical outcome data.

Executives

5am Partners Iv, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Erin K. Brenner	officer: Chief Product Dev. Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Julia Strandberg	officer: Chief Commercial Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ronan O'brien	officer: General Counsel & Secretary	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Mccann Corey	director, officer: President and CEO	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Yuri Maricich	officer: Chief Medical Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ellen Snow	officer: Chief Accounting Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Christopherd T Guiffre	officer: CFO, COO, Treas., & Asst. Sec.	65 HAYDEN AVE, LEXINGTON MA 02421
Katherine Jeffery	officer: Chief People Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Paul Mango	director	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Timothy A Wicks	director	C/O PRECISION CASTPARTS CORP., 4650 SW MACADAM AVENUE, SUITE 400, PORTLAND OR 97239
Shivakumar Rajaraman	director	6260 LOOKOUT ROAD, BOULDER CO 80301
Klp Spac 1 Llc	10 percent owner	195 CHURCH STREET , 15TH FLOOR, NEW HAVEN CT 06510
Zack Lynch	director	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Elbrus Investments Pte. Ltd.	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891